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ENVIRONMENTAL RISK FACTORS FOR BRONCHOPULMONARY DYSPLASIA
(BPD). Jessica Berger, Paulomi Mehta, Emily Bucholz, James Dziura, and Vineet
Bhandari. Section of Neonatology, Department of Pediatrics, Yale University, School of
Medicine, New Haven, CT.
We hypothesized that early intubation would decrease the hazard of BPD and BPD/death
in premature infants regardless of need for reintubation. Specific aims included assessing
rates of BPD and BPD/death in infants first extubated between day of life (DOL)1-3
versus 4-7, 8+ and impact of re-intubation. We included infants with gestational age
≤28weeks, birth weight ≤1000g, and intubation on DOL1. Proportional hazards
regression modeled time to BPD and BPD/death, adjusting for potential confounders. Of
262 infants, 101 (38.55%), 41 (15.65%) and 120 (45.80%) were extubated between
DOL1-3, 4-7, and 8+, respectively. Extubation between DOL4-7 versus DOL1-3 was
associated with an increased hazard of developing BPD (HR 1.7; 95%CI 1.0-2.8;
p<0.05). Extubation on DOL 8+ was associated with a significantly increased hazard
compared to extubation between DOL1-3 (16.9; 10.5-27.1; <0.0001) or DOL4-7 (10.0;
6.1-16.3; < 0.0001). Similar results were noted with BPD/death. Re-intubation did not
affect BPD and BPD/death. Delaying extubation beyond the first 3 and 7 days was
associated with an increased risk of BPD and BPD/death. Re-intubation did not impact
outcomes.
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INTRODUCTION
Disease Overview
Bronchopulmonary dysplasia (BPD) is one of the most common co-morbidities of
premature birth. In 1967, William H. Northway, Jr. published the earliest known
description of BPD, a “chronic pulmonary syndrome” which he believed to be a
consequence of therapy for neonatal respiratory distress syndrome (RDS). Northway
characterized BPD by the radiographic and histopathologic changes occurring in the
neonatal lungs after a period of rigorous invasive mechanical ventilation and highconcentration supplemental oxygen. In a retrospective and post-mortem (when
applicable) study of 32 premature infants, Northway observed that those treated with
prolonged invasive ventilation and supplemental oxygen therapy had difficulty breathing
in room air when weaned from the ventilator. In those infants with evolving chronic lung
disease, the lungs appeared bullous on chest x-ray. The radiographic appearance was
reflected pathologically as well, with areas of bullous emphysema surrounded by areas of
atelectasis. Histologically, there was also evidence of a thickened, fibrotic basement
membrane and bronchial smooth muscle hypertrophy. Clinically, many of the infants also
had concurrent pulmonary hypertension and cor pulmonale 1.
Since Northway’s initial characterization of BPD, scientists and clinicians have
gathered a wealth of knowledge about the disease using animal models, retrospective
clinical analysis, and randomized clinical trials. From a basic science perspective, these
studies have broadened our understanding of the disease’s etiology and pathogenesis.
Recent histologic investigation has offered a “new” pathologic definition of BPD. “New”
BPD is characterized by decreased alveolar septation and irregular development of the

	
  

6	
  
pulmonary microvasculature rather than pulmonary fibrosis

2,3

. In addition, “new” BPD

does not always evolve from RDS 4.
Clinical criteria for diagnosis have also evolved over time. Prior to 2001, BPD
was diagnosed only by a need for supplemental oxygen at 36 weeks’ post-menstrual age
(PMA). In 2001, a collaborative effort by the National Institute of Child Health and
Human Development, the National Heart, Lung, and Blood Institute, and the Office of
Rare Diseases yielded a set of new diagnostic criteria, known colloquially as the NIH
Consensus Definition. The NIH Consensus Definition categorizes BPD by severity using
a scale based on the number of days of supplemental oxygen use, as well as oxygen and
positive pressure ventilation requirements at 36 weeks’ PMA. Any diagnosis of BPD
requires a minimum of 28 days of supplemental oxygen use. Infants with mild BPD no
longer require supplemental oxygen at 36 weeks’ PMA or time of discharge, whereas
infants with moderate and severe disease require a fraction of inspired oxygen (FiO2) <
30% or FiO2 > 30% supplemental oxygen, respectively. A diagnosis of moderate or
severe disease may be made if an infant requires positive pressure ventilation at 36
weeks’ PMA even if FiO2 requirements are not met 2. Walsh et al proposed a
“physiologic definition of BPD” based on FiO2 and oxygen saturations during an oxygen
reduction test at 36 weeks’ PMA in order to reduce discrepancies in diagnosis between
physicians 5.
Disease Epidemiology
Previous studies have estimated rates of BPD between 22% and 68% of pre-term
neonates 6,7. This variability in incidence may be attributed to the range of gestational age
(GA) and birth weight (BW) of the study populations and the use of differing definitions
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of BPD. Of note, the 2001 definition includes babies who would not have been diagnosed
with BPD using earlier criteria. Consistently lower rates of BPD were seen across centers
that used the physiologic definition of BPD 8. Lower BW and/or lower GA are correlated
with an increased incidence of BPD 6,7, with 97% of BPD diagnoses occurring in infants
weighing < 1250 g at birth 9.
Management of BPD
Inherent to the definition of BPD is the prolonged use of positive pressure
ventilation and supplemental oxygen. Conventional mechanical ventilation and highfrequency oscillatory ventilation are two modalities frequently used to support infants
with BPD. Guidelines based on ventilator settings and arterial blood gases dictate when
an infant may be extubated. In some severe cases, infants fail several attempts at
extubation due to severity of disease or anatomical reasons, which may result in a
tracheotomy for long-term respiratory support. Supplemental oxygen therapy aims to
achieve an appropriate balance between hypoxia and hyperoxia, both of which may be
detrimental 10. To date, there remains a paucity of evidence as to what oxygen saturation
range is optimal, though > 90% and < 95% are commonly-used thresholds

3,10

. Some

infants may be discharged from the hospital with supplemental oxygen by nasal cannula
for ongoing support, growth and development 10.
In addition to supplemental oxygen and assisted ventilation, there are many
therapies used to mitigate the effects of BPD. Post-natal steroids are often used to
facilitate extubation, particularly in infants who have been invasively ventilated for long
periods or who have had repeated extubation failures. In previous studies, dexamethasone
worked well for this purpose. Steroid use has been associated with poor long-term
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neurocognitive outcomes 3. Diuretics are commonly used to reduce pulmonary edema, a
frequent occurrence in infants with BPD. Data are mixed as to the appropriate classes of
diuretics that should be used and their long-term efficacy, but one meta-analysis has
shown a short course of a thiazide diuretic combined with spironolactone to reduce
mortality and aid with lung compliance

11

. Concurrent pulmonary hypertension may

require pulmonary vasodilators such as inhaled nitric oxide or sildenafil 10.
Long-Term Morbidity
Prevention of BPD has substantial implications for reducing health care
expenditures and long-term morbidity of premature infants.
Health care costs: Many of the comorbidities commonly linked to preterm birth are
associated with increases in health care costs. High costs in the setting of BPD are
primarily a consequence of prolonged respiratory support and increased length of
intensive care unit stays 12.
Respiratory sequelae: Long-term respiratory sequelae of BPD may persist into childhood
and even adulthood. One analysis of infants with BPD demonstrated 50% and 36% rates
of re-hospitalization in the first and second years of life, respectively. Further, infants
with BPD were at increased risk for pulmonary infections and reactive airway disease 13.
Analyses of long-term respiratory outcomes suggest that subjective respiratory symptoms
such as cough and wheeze continue well into adulthood 14,15. The EPICure study showed
an association between extreme prematurity and reduced lung function by the age of 11.
The study demonstrated an even greater reduction in lung function for children with a
history of BPD 16.
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Neurocognitive outcomes: Short et al. showed neurocognitive deficits on validated
assessments in 8-year olds with BPD. Increased severity of BPD was correlated with
poorer neurocognitive outcomes. It was also observed that Attention DeficitHyperactivity Disorder was more common in the BPD group than control groups. Use of
post-natal steroids as part of therapy for BPD was also associated with poorer outcomes
17,18

.

Disease Etiology and Pathogenesis
Studies done in animal models and in human subjects have shown that the
etiology of BPD is multi-factorial.
Genetic susceptibility: Previous studies have discovered a genetic component to the
etiology of BPD. A detailed discussion of these studies and techniques used to elucidate
genes of interest can be found in Chapter 2.
Antenatal Factors: There is also evidence that environmental factors play a role in BPD
pathogenesis. Intrauterine infection, or chorioamnionitis, has been associated with the
development of BPD. Intra-amniotic infection drives pro-inflammatory changes
including increased cytokine concentrations that may predispose infants to prematurity as
well as impaired lung maturation 4. Ureaplasma urealyticum is a frequently-studied
bacterium associated with BPD 19.
Postnatal Factors: Though invasive ventilation and supplemental oxygen are mainstays
in the early management of preterm neonates, paradoxically, prolonged exposure to these
therapies is a known cause of BPD. Invasive mechanical ventilation damages lung tissue
by several mechanisms. Mechanical stretch from over-inflation, atelectasis from low tidal
volumes, and predisposition to infection from foreign body colonization contribute to
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excess inflammation in the developing lungs. Inflammation and the subsequent tissue
remodeling ultimately lead to a disruption of normal lung architecture

13,20

. Prolonged

exposure to hyperoxic conditions may damage lung tissue through free radical formation
13

.

Minimizing Invasive Ventilation
Given the known impact of prolonged ventilation on the incidence of BPD,
reduction of ventilator trauma early in post-natal life remains an important subject for
inquiry. Two large trials, the Continuous Positive Airway Pressure or Intubation at Birth
(COIN) Trial and the Surfactant, Positive Pressure, and Oxygenation Randomed
(SUPPORT) Trial, investigated the incidence of BPD or death in infants randomized
shortly after birth to either nasal continuous positive airway pressure (NCPAP) or
endotracheal intubation. The investigators of the COIN Trial found that infants
randomized at five minutes of life to CPAP had significantly lower rates of death or
oxygen use by day of life (DOL) 28 and spent fewer days on the ventilator overall.
However, there was no significant difference in the rates of BPD or death between the
CPAP group and the intubation group at 36 weeks’ PMA. Nearly half (46%) of infants in
the CPAP group required intubation by DOL 5. Additionally, infants initially receiving
CPAP had higher rates of pneumothorax 21. The SUPPORT Trial randomized infants to
NCPAP or intubation with surfactant administration by one hour of life. There was no
significant difference in the primary outcome of BPD or death at 36 weeks’ PMA. When
stratified by gestational age, post-hoc analysis did reveal a significant reduction in BPD
or death at 36 weeks’ GA for infants born between 24 weeks 0 days and 25 weeks 6 days.
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The CPAP group also had lower rates of death and intubation by DOL 7 and fewer days
of ventilation overall 22.
Many premature infants are too critically ill at birth for NCPAP to be a viable
option. For those infants, reducing the number of days spent invasively ventilated is
crucial to preventing or minimizing adverse outcomes. In a study of infants < 1500 g
invasively ventilated up to DOL 7, DOL 14, and beyond DOL 15, Gonzaga et al.
demonstrated that the hazard of developing BPD is correlated directly with prolonged
invasive ventilation 23. Though invasive ventilation beyond week one has been associated
with development of BPD, few investigators have studied the impact of ventilator use at
different points during the first week of life.
One such study, by Dumpa et al., demonstrated that predominant use of noninvasive forms of ventilation (NCPAP or non-invasive intermittent positive pressure
ventilation (NIPPV)) during the first week of life significantly reduced the incidence of
BPD compared to endotracheal intubation. In addition, this study showed that babies
extubated to NIPPV by DOL 7 were at a reduced risk of BPD or death compared to
babies who remained invasively ventilated through the end of the first week of life. The
sample size was not adequate, however, to study the effect of reintubation on BPD

24

.

Concerns about potential reintubation continue to play a major role in the decision to
extubate despite a lack of evidence directly linking reintubation with poor long-term
outcomes 25.
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STATEMENT OF PURPOSE/ SPECIFIC AIMS
Based on the existing literature and clinical experience, we predicted that early
extubation would reduce the incidence of BPD. Given that many early attempts at
extubation fail, we also examined whether neonates who fail early extubation and need to
be reintubated would still have a decreased incidence of BPD as compared to babies
successfully extubated later in life.
To explore these hypotheses, we aim to:
(1) Identify infants at the greatest risk of developing BPD who were hospitalized at
Yale-New Haven Children’s Hospital between January 2006 and December 2011.
(2) Collect retrospective clinical data about these infants, particularly with respect to
mechanical ventilation and DOL of extubation.
(3) Use clinically accepted criteria to group infants by outcomes of BPD, no BPD, or
death.
(4) Use appropriate statistical methods to assess for statistical differences in the
hazard of BPD or death across study groups.
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METHODS
Patient Population
Retrospective clinical data were collected on all infants hospitalized in the YaleNew Haven Children’s Hospital Neonatal Intensive Care Unit (NICU) between January
1, 2006 and December 31, 2012. Criteria for inclusion were all of the following: GA ≤ 28
weeks, BW ≤ 1000 g, and intubation on DOL 1. Infants who died on DOL 1, lacked any
attempts at extubation, or were born with significant congenital cardiopulmonary
anomalies were excluded. If a pair of twins met the inclusion criteria, one infant from the
pair was randomly included to preserve the independence of study subjects for analysis
and to avoid inclusion bias by birth order. Outcomes for the study included diagnosis of
BPD, as defined by NIH consensus,2 and a composite outcome of BPD or death from any
cause prior to 36 weeks’ PMA.
Data collection
Data were collected from the Yale NICU database and supplemented with the
electronic medical record. The study was approved by Yale University’s Human
Investigation Committee.
Demographic data included maternal, fetal, perinatal, and neonatal variables.
Maternal data included race, prenatal care, and antenatal steroid administration. As in
previous studies, antenatal steroids were only recorded if given at least 12 hours prior to
delivery

24

. Fetal variables included multiple gestation, gender, GA, and BW. Perinatal

variables were collected on mode of delivery, APGAR scores at 1 and 5 minutes postpartum, delivery room resuscitation details including use of supplemental oxygen (O2),
bag and mask ventilation (BMV), ETT intubation, chest compressions, and/or
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epinephrine, and diagnosis of respiratory distress syndrome (RDS) documented by
clinical and radiographic findings. Use of NCPAP prior to ETT intubation was also
documented.
Neonatal variables included surfactant use either at delivery or at any point during
hospitalization and data on common co-morbidities and treatment where applicable.
These included retinopathy of prematurity (ROP), intra-ventricular hemorrhage (IVH),
sepsis documented by positive blood culture, necrotizing enterocolitis (NEC), patent
ductus arteriosus (PDA) and treatment with indomethacin, ibuprofen, and/or ligation,
gastrointestinal perforation, periventricular leukomalacia (PVL), and pneumothorax or
pneumomediastinum documented by chest radiograph. Post-natal steroid use was also
recorded.
Definitions of neonatal comorbidities used were previously outlined by our
research group
26

24

. ROP stage was assigned using the international classification scheme

. IVH was staged using the system described by Papile

27

. Cases of NEC satisfying

stage II or greater by Bell’s criteria were included 28. Diagnosis of PDA was confirmed
by echocardiography. PVL was identified by observation of echogenicity and cystic
lesions in the periventricular white matter on cerebral ultrasound 29.
During the study period, there were standard guidelines in place in our NICU for
delivery room (DR) management, intubation, surfactant administration, extubation, noninvasive ventilation support, re-intubation and postnatal steroid use.

In brief, our

approach after initial stabilization in the DR was to support neonates on NCPAP, to a
maximum 6 cmH2O, in the NICU. If requiring ≥0.35 FiO2, infants were intubated and
surfactant administered, if indicated for those with RDS (based on clinical/radiographic
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criteria) 30. All infants were started on caffeine, prior to any extubation attempt, usually
within the first 24h of life, and continued till they were off respiratory support. Infants
were weaned on the ventilator settings and extubated to NIPPV, as per standard practice
in our NICU, based our published guidelines 31. Specific instructions were in place in our
NICU for NIPPV use, and specific criteria were used for re-intubation, if required 31. Use
of postnatal steroids was mostly restricted to a 5-day course of dexamethasone to
facilitate extubation, utilized after 4 weeks of postnatal life. As the infants improved, as
per our published guidelines, they were weaned off NIPPV, to NCPAP and then nasal
cannula 31. All infants underwent an oxygen-reduction test at 36 weeks PMA to assess the
presence and/or severity of BPD.
Variables concerning the infant’s postnatal course were collected from medical
and respiratory therapy records, such as DOL of first attempted extubation, need for
reintubation, DOL of all subsequent extubation and reintubation attempts, number of
days on each ventilator modality, number of days receiving supplemental O2, and length
of stay in the NICU. Supplemental O2 was defined as FiO2 > 0.21.
Infants were divided into three study groups by DOL of first attempted
extubation: DOL 1-3, DOL 4-7, and DOL 8+. These groupings were based on those
previously studied by Dumpa et al

24

. Extubation attempts were defined as purposeful

attempts to remove the ETT. We included accidental extubation only if a decision not to
replace the ETT was documented. Reintubation was defined as non-elective replacement
of ETT at any time after extubation. Reintubation for elective or semi-elective surgical
procedures such as ROP laser surgery, hernia repair, or bowel re-anastomosis were not
included, as the majority of these cases occurred after 36 weeks’ PMA. Additionally,
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elective reintubation has not been shown to affect respiratory outcomes in infants
previously diagnosed with BPD 32.
Statistical Analyses
Baseline maternal, fetal, perinatal, and neonatal characteristics were compared
across our three study groups using chi-squared tests or Fisher’s exact test, where
appropriate, for categorical variables and one-way ANOVA for continuous variables. We
used chi-squared tests or Fisher’s exact test to compare crude rate of BPD/death between
the three groups. We used these same tests to compare crude rates of BPD/death based on
DOL of extubation and need for reintubation, as well as the breakdown of BPD severity
by extubation group.
We used Kaplan-Meier curves to model the unadjusted probability of survival
without BPD/death between the DOL of first extubation and 36 weeks’ PMA. We set
time “0” at DOL of first extubation, which varied by infant, and modeled the time course
from extubation to an outcome (“BPD,” “no BPD,” or “death”). For infants hospitalized
at our institution through 36 weeks PMA, data collection was discontinued at 36 weeks’
PMA and outcomes were assessed at that time. An outcome of “death” was assigned at
the DOL that the event occurred prior to 36 weeks’ PMA. The log-rank test was used to
compare the probability between the three groups of disease-free survival as a function of
time from DOL of first extubation to an outcome of BPD/death.
In a minority of cases, infants were discharged from the NICU either to home or
to another institution prior to 36 weeks’ PMA (N = 31). If at time of discharge prior to 36
weeks’ PMA the infant had already received ≥ 28 days of supplemental oxygen, an
outcome of BPD was assigned at the DOL equivalent to 36 weeks’ PMA (N=15). Sixteen
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infants who were discharged or transferred prior to 36 weeks’ PMA had not received at
least 28 days of supplemental oxygen by time of discharge. Three of these infants were
discharged to home because the infant was deemed healthy enough for discharge; the
likelihood of a subsequent BPD diagnosis was miniscule and these infants were
designated as “no BPD.” For the 13 infants transferred to outside institutions prior to 36
weeks PMA, we used clinical judgment, including DOL of transfer, and status at time of
transfer, including cumulative days of O2 therapy, ventilator modality, and FiO2 at time
of transfer to assign the most probable outcome at 36 weeks’ PMA. Based on clinical
judgment, we assumed that their clinical course at another institution would categorize
eight as “no BPD” and five as “BPD.” To assess for potential bias based on transfer of
infants and use of clinical judgment to designate outcomes for a minority of subjects, we
also performed the proportional hazards analyses discussed below with these 13 infants
omitted.
Cox proportional hazards models were used to calculate the unadjusted hazard of
developing one of the primary outcomes based on DOL of extubation. Cox proportional
hazards regression was used to model the hazard of developing BPD and BPD or death
by adjusting for potential confounders and known contributors to BPD and/or death.
Covariates were selected a priori using a combination of clinical judgment and statistical
testing. They included antenatal steroid use, race, gender, multiple gestation, GA,
APGAR at 5 minutes, mode of delivery, delivery room resuscitation efforts, RDS,
surfactant use, ROP, IVH, NEC, sepsis, PDA, bowel perforation, PVL, pneumothorax,
pneumomediastinum, and need for reintubation. Variables inherent to the definitions of
the study groups or the definitions of BPD, such as days intubated, days on supplemental
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O2, or post-natal steroid use, were excluded. Given the degree of correlation between GA
and BW, we compared models fit with each variable using Akaike Information Criterion
(AIC) values and concluded that GA produced a better-fit model than BW, though both
models produced similar estimates. To evaluate whether reintubation modified the
association between DOL at extubation and development of BPD or death, we included
interaction terms between extubation DOL and reintubation in our model.
Data are shown as hazard ratios (HRs) with 95% confidence intervals (CI). A pvalue of 0.05 was used to determine statistical significance.
For analysis of patient demographics and rates of reintubation, we used GraphPad
PRISM software, Version 6.0a (GraphPad Software Inc., San Diego, CA). For KaplanMeier analysis and proportional hazards modeling, we used SAS software, Version 9.3
for Windows (SAS Institute Inc., Cary, NC). For Kaplan-Meier analysis, we used the
lifetest procedure. For unadjusted and adjusted proportional hazards modeling, we used
the phreg procedure. To study the interaction of extubation DOL and reintubation, we
used the phreg procedure with customized contrast statements.
Division of Efforts
The student was responsible for selection of study subjects, data collection and
analysis of data. Statistical advice was provided by James Dziura, PhD (Yale Center for
Analytical Sciences) and Emily Bucholz, MPH/PhD candidate (Yale School of Public
Health). Our statistical advisors offered advice regarding which procedures to use and
how to develop the initial code for the SAS software. The student then used the code
provided to analyze the data and apply changes to the code when necessary.
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RESULTS
Patient Categories
After applying inclusion and exclusion criteria, the final cohort included 262
infants (Supplemental Fig. 1). Of these, 101 (38.5%) were extubated between DOL 1-3,
41 (15.6%) were extubated between DOL 4-7, and 120 (45.8%) were extubated DOL 8+.
Patient Characteristics
Table 1 shows the characteristics of the sample by DOL at extubation. There
were no significant differences in maternal variables. Multiple gestation and RDS were
significantly more common in the late extubation group. The babies who were extubated
earlier tended to be older and heavier, with higher APGAR scores at 5 minutes.
Comorbidities including IVH, ROP, and PDA occurred with greater frequency in the late
extubation group. Infants who were extubated later were significantly more likely to have
received postnatal steroids. Additionally, infants who were extubated later had longer
hospital stays.
Unadjusted rates of BPD and BPD or death increased with duration of initial
intubation (Table 2A). Forty-seven (46.5%) babies extubated between DOL 1-3, 31
(75.6%) babies extubated between DOL 4-7, and 112 (93.3%) babies extubated DOL 8+
were diagnosed with BPD, respectively. Additionally, 11 infants extubated between DOL
1-3, 1 infant extubated between DOL 4-7, and 4 infants extubated DOL 8+ died prior to
36 weeks’ PMA.
Rates of reintubation did not differ significantly between the three groups (Table
2A). Unadjusted rates of BPD and BPD or death were higher among reintubated infants
in the DOL 1-3 and DOL 4-7 study groups compared to non-reintubated infants (Table
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2B), but this only achieved statistical significance for the infants extubated between DOL
1-3 (BPD: p < 0.05; BPD or death: p = 0.0004). This did not hold true for infants
extubated between DOL 4-7 (BPD: p = 0.008; BPD or death: p = 0.05) or DOL 8+ (BPD:
p = 0.4; BPD or death: p = 1.0). We did not identify any significant differences in the
severity of BPD by DOL of extubation (Table 3).
Unadjusted Time to BPD or Death
Kaplan-Meier survival curves for our cohort modeled the probability of
BPD/death-free survival following the DOL of initial extubation (Fig. 1A-B). The BPD
plot (Fig. 1A) shows a significant difference in BPD-free survival across study groups (p
< 0.0001). The plot shows that infants extubated on DOL 8+ are more likely to develop
BPD in a shorter period of time following initial extubation than infants extubated DOL
1-3 or DOL 4-7. This reflects the fact that these infants are extubated later in life, far
closer to 36 weeks’ PMA than infants in the other study groups, and are developing BPD
at a higher rate. This difference is also seen between the curves for infants extubated
DOL 1-3 and DOL 4-7. For the BPD-only analysis, the 16 infants who died prior to 36
weeks’ PMA were censored at DOL of death, represented by a hash mark on the plot. All
other infants with an outcome of “no BPD” or “no BPD or death” were censored at 36
weeks’ PMA, also represented by a hash mark. The BPD or death plot (Fig. 1B) also
shows significant differences in event-free survival over time (p < 0.0001). The early
downward slope in the DOL 1-3 curve reflects the 11 deaths in the DOL 1-3 group in the
first weeks of life. The curve for the DOL 1-3 group subsequently plateaus, showing a
greater probability of event-free survival over time than the other study groups, in
particular DOL 8+. Both the BPD and BPD or death plots also reflect the GA of each
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infant, as the number of days to 36 weeks’ PMA is variable based on GA of each infant
in addition to DOL of extubation.
The unadjusted hazard of BPD increased with greater length of initial intubation
(Table 4A). Infants who were first extubated between DOL 4-7 had an increased, though
not significant, risk of developing BPD compared to babies who were first extubated
between DOL 1-3 (p = 0.09). Extubation on DOL 8+ was associated with a significantly
increased risk of BPD compared to extubation between DOL 1-3 (p < 0.0001) or
extubation between DOL 4-7 (p < 0.0001). Similar results were observed when the
composite outcome of BPD or death was modeled (Table 4B). Extubation between DOL
4-7 was associated with a non-significantly increased hazard compared to extubation
between DOL 1-3 (p = 0.3). Extubation on DOL 8+ was associated with a significantly
increased hazard compared to extubation between DOL 1-3 (p < 0.0001) or between
DOL 4-7 (p < 0.0001).
Adjusted Time to BPD or Death
After adjustment for maternal and infant characteristics, differences in outcomes
between extubation groups became more pronounced (Tables 4A and 4B). Extubation
between DOL 4-7 was associated with an increased hazard of developing BPD compared
to extubation between DOL 1-3 [HR (95% CI) 1.7 (1.0-2.8), p < 0.05], but not
significantly so with BPD or death [1.3 (0.8-2.2), p=0.3]. Extubation on DOL 8+ was
associated with a significantly increased hazard of BPD and BPD or death compared to
extubation between DOL 1-3 [BPD: 16.9 (10.5-27.1), p<0.0001; BPD or death: 10.7
(7.0-16.5), p<0.0001] or extubation between DOL 4-7 [BPD: 10.0 (6.1-16.3), p<0.0001;
BPD or death: 8.1 (5.0-13.0), p<0.0001].
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To evaluate whether reintubation modified the association between time at first
extubation and development of BPD or death, we examined interactions terms in our
model. The predictor variable was DOL of first extubation and the modifier was
reintubation. Successful first extubation between DOL 4-7 was associated with an
increased hazard of BPD when compared to unsuccessful extubation between DOL 1-3
but was not statistically significant [BPD: 1.4 (0.5-4.0), p = 0.6; BPD or death: 1.0 (0.32.9), p = 1.0]. Successful first extubation on DOL 8+ was associated with a significantly
increased hazard of BPD and BPD or death compared to unsuccessful extubation between
DOL 1-3 [BPD: 25.0 (13.4-46.5), p < 0.0001; BPD or death: 12.0 (6.8-21.1), p <
0.0001] or unsuccessful extubation between DOL 4-7 [BPD: 14.4 (7.8-26.8), p < 0.0001;
BPD or death: 9.5 (5.2-17.3), p < 0.0001].
As described in the methods, cox proportional hazards modeling and adjusted
analyses of interactions terms were also performed after omission of the 13 infants
transferred or discharged prior to 36 weeks’ PMA who did not meet criteria for BPD
upon discharge. In this separate analysis, the magnitude and statistical significance of the
hazard ratios were qualitatively similar.
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DISCUSSION
Our retrospective analysis demonstrated that early extubation of preterm neonates
is associated with a significantly reduced hazard of BPD when compared to extubation
later in life. Importantly, we also show that babies who failed early extubation and
needed to be reintubated remained at a lower hazard of BPD than babies who were first
extubated later in life and did not need to be reintubated. Delayed extubation was also
associated with increased hazard of BPD or death, though the association was not as
strong as for BPD alone.
Compared to the previous literature, our study takes a novel approach by studying
the interaction effect crossing the variables extubation DOL and reintubation to model the
risk of BPD/death. In addition, we used a different statistical approach than previous
work in this area. The use of survival analysis allowed us to model time to BPD and BPD
or death and to account for censoring. This was useful, as time to BPD and BPD or death
vary by extubation DOL and also by GA.
Our study builds upon previous work done in the field. We confirmed the
conclusion by Dumpa et al that delayed extubation in the first week of life is associated
with increased risk of BPD/death

24

. This observation is also consistent with studies in

animal models. Thomson et al have shown that preterm baboons extubated to NCPAP at
DOL 5 needed more oxygen and had a greater degree of hypercapnea than baboons
extubated at 24 hours of life. An equal number of animals in both groups required
reintubation, but those in the delayed extubation group had more reintubation events on
average and spent more cumulative days on the ventilator 33.
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Few studies have looked at the effect of early extubation on the rate of
reintubation and the rate of BPD. In a retrospective analysis, Booth et al showed success
rates of 66% of extubations to NCPAP on DOL 1 and 80% on DOL 2. However, the
study lacked an adequate sample size to predict success for extubations after DOL 2.
Booth et al observed a statistically significant difference in rates of BPD for infants
extubated by DOL 2 compared to those still on conventional ventilation. This result
correlates to the reduced hazard of BPD we found in our DOL 1-3 study group, but the
Booth et al study did not analyze reintubation with respect to BPD

34

. In a randomized

control trial, Danan et al selected preterm infants for extubation immediately or after 36
hours of life. There was no significant difference in reintubation rates between groups.
Rates of BPD at 36 weeks’ PMA were also not significantly different between the groups
35

. We also showed no significant difference in extubation failure based on DOL of first

extubation. Both of Danan et al’s study groups would fit within our DOL 1-3 study
group, which may account for the absence of difference in BPD between groups. The
differences we observed for BPD across study groups may be further attributed to our use
of the NIH Consensus to define BPD and our larger sample size. One unpublished study
by Robbins et al showed an inverse correlation between DOL of first extubation and
BPD. Using linear regression and correlation analysis, this group showed a significant
correlation between DOL of extubation and need for reintubation, but found no
association between need for reintubation and BPD 36.
Predicting extubation readiness in neonates in order to reduce extubation failures
is important, but imprecise. Though investigators have studied different measures to
predict success, there is no consensus as to the best method to predict successful
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extubation 37-41. One method, the 3-minute spontaneous breathing trial (SBT), was shown
to be safe and feasible by a prospective, non-randomized control study. However,
outcomes for the SBT in days invasively ventilated, rates of extubation failure, and rates
of BPD do not differ significantly from clinical judgment alone 42. Other efforts to reduce
extubation failure vary in their efficacy. A trial of a new model of ultrathin-walled twostage twin ETT did result in significantly fewer reintubations compared to a conventional
ETT, yet did not significantly reduce the overall number of days ventilated or the rates of
BPD 43.
Data on the long-term impact of reintubation in neonates are limited. Studies
suggest that the long-term impact of reintubation varies based on the number of events
and the technical skills of the clinician. Prolonged invasive ventilation itself is a risk
factor for extubation failure 25, which supports the case for early extubation. We showed
similar rates of extubation failure across all study groups. Though we found that a
successful, delayed extubation was associated with an increased hazard of BPD or death
when compared to a failed early extubation, further study is needed to confirm this
observation. Early extubation combined with better methods to prevent extubation failure
would likely improve outcomes for all infants. Aside from improving respiratory
outcomes, other benefits of early extubation may include reduced exposure to painful
procedures and smaller cumulative doses of analgesic medications 44.
One possible explanation for our observations is that early extubation reduces
harmful systemic inflammation during the first 72 hours of life. In neonates ≤ 30 weeks’
GA, Chang et al measured the levels of pro-inflammatory cytokines interleukin (IL)-6,
IL-8, and granulocyte- colony stimulating factor (G-CSF) between DOL 1-42.
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Remarkably, levels of these three cytokines, which are commonly elevated during
periods of active infection, were elevated between DOL 1-3 in infants in the absence of
clinical, bacteriological or placental histological evidence of infection 45. These first few
days of postnatal life may represent a critical temporal window of a propensity to an
exaggerated inflammatory response in neonates exposed to intensive care. It may be that
extubation during this critical period reduces the burden of inflammation and subsequent
lung damage even if the infant is eventually reintubated. Most studies of pulmonary
biomarkers have shown an early increase in pro-inflammatory cytokines from tracheal
aspirate samples obtained from infants subsequently developing BPD 46. Given the major
drawback in these studies of the absence of samples from non-intubated infants, further
study is needed to sequentially track inflammatory markers (perhaps, in nasopharyngeal
secretions

47

) in response to invasive versus non-invasive ventilation to test the

speculation.
Our study has limitations. Since our study is retrospective, our conclusions are
only observational. Though much of our data were provided by the Yale NICU database,
we relied upon the accuracy of the electronic medical record for extubation and
reintubation DOL, as well as FiO2 levels, which were needed to assess our outcomes. As
discussed in the methods, sixteen infants were discharged or transferred prior to the end
of the study. While three of these infants were deemed healthy enough for discharge and
were unlikely to ever develop BPD, thirteen infants were transferred to other facilities.
Using clinical judgment, we assigned what we deemed to be the most likely outcome at
36 weeks’ PMA. Though these assignments could not be made unequivocally, we based
them on clinical data including DOL and respiratory requirements at time of transfer.
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Only five of these infants were transferred while still receiving oxygen therapy. We
believe that this small number of infants would be unlikely to significantly affect our
results. We also sought to ensure that including or excluding these 13 infants would not
bias our study and found no differences in the resulting data with these infants included
or omitted.
Our analysis of the effect of reintubation also has some limitations. For this study,
we documented all necessary reintubations, with the exception of elective intubations for
surgery after 36 weeks’ PMA. We did not perform separate analyses based on the reason
for reintubation or based on the time to extubation failure. We recognize that an
understanding of the reasons for and timing to extubation failure may provide important
clinical information that can further elucidate our conclusions, and we aim to address
these analyses in a subsequent manuscript. In our analysis, we investigated the impact of
at least one reintubation on our outcomes. We did not study the effect of multiple
reintubations as compared to a single reintubation. However, since the outcome of BPD
and/or death was assessed at 36 weeks PMA, any potential impact of prolonged
intubation due to multiple reintubations until that time point would have been
incorporated.
We employed several strategies to strengthen our study and overcome inherent
limitations. We used a large sample size to increase the power of our observations,
focused our study on the subset of premature infants most vulnerable to BPD, and used
the NIH Consensus definition to assign our outcomes. To minimize potential inaccuracies
in our database, variables were confirmed by crosschecking with the electronic medical
record. We utilized consistent data collection methods throughout.
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In conclusion, delaying extubation beyond the first days of life, and certainly
beyond the first week of life, is associated with an increased risk of BPD and BPD or
death. We believe that we have controlled for the major confounding variables that could
impact on the degree of illness in the infant – an important factor in keeping the neonate
intubated. Anecdotal evidence in our NICU suggests that despite guidelines to attempt
extubation when specific ventilation settings are reached, this is not always done. We
have previously reported that fear of “growth failure” on non-invasive ventilation should
not deter one to attempt an extubation 48. Cooperation with trained respiratory therapists
on therapist-driven weaning protocols shows promise in achieving more successful early
extubations and decreasing the overall length of invasive ventilation 49.
The high observed rate of reintubation for all infants in our study and the fact that
reintubation was not associated with an increased hazard of BPD imply that potential
need for reintubation should not necessarily impede early attempts at extubation. We
recognize that other factors such as infection or need for surgery often affect the decision
to extubate and that not all infants can be optimized for extubation in the first days of
life. However, in the absence of extenuating circumstances, we recommend that
extubation of infants who have been sufficiently weaned not be delayed, as our data show
prolonged invasive ventilation to be associated with an increased hazard of BPD.
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Table 1. Demographics of the Study Groups
Extubated DOL Extubated
1-3 (N = 101)
DOL 4-7 (N = 41)
Antenatal steroids, n 91 (90.1)
36 (87.8)
(%)
Race, n (%)
Caucasian
43 (42.6)
15 (36.6)
African American
35 (34.7)
18 (43.9)
Asian, Hispanic, and 23 (22.8)
8 (19.5)
Other
Male gender, n (%)
49 (48.5)
23 (56.1)
Multiple gestation, n 14 (13.9)
13 (31.7)
(%)†
Caesarean delivery, n 69 (68.3)
32 (78.0)
(%)
Gestational age (wks)* 26.02 ± 1.0
25.7 ± 1.2
†
Birth weight (g)* †
809.4 ± 113.6
784.2 ± 127.4
APGAR 1 minute**
5 (1-8)
4 (0-9)
APGAR 5 minutes**† 7 (2-9)
6 (1-9)
DR Oxygen, n (%)
100 (99.0)
41 (100.0)
DR BMV, n (%)
98 (97.0)
38 (92.7)
DR Intubation, n (%) 94 (93.1)
33 (80.5)
DR
Chest 13 (12.9)
12 (29.3)
Compressions, n (%)
DR Epinephrine, n 4 (4.0)
2 (4.9)
(%)
DR Surfactant, n (%) 46 (45.5)
18 (43.9)
NCPAP prior to ETT, 9 (8.9)
8 (19.5)
n (%)
RDS, n (%)†
84 (83.2)
38 (92.7)
Anytime surfactant, n 98 (97.0)
40 (97.6)
(%)
Postnatal steroids, n 17 (16.8)
9 (22.0)
(%)†
IVH, n (%)†
23 (22.8)
18 (43.9)
ROP, n (%)†
54 (53.5)
25 (61.0)
NEC, n (%)
26 (25.7)
9 (22.0)
Bowel Perforation, n 6 (5.9)
3 (7.3)
(%)
PDA, n (%)†
19 (18.8)
16 (39.0)
Sepsis, n (%)
24 (23.8)
13 (31.7)
PVL, n (%)
2 (2.0)
2 (4.9)

	
  

Extubated DOL
8+ (N = 120)
109 (90.8)
47 (39.2)
41 (34.2)
32 (26.7)
59 (49.2)
31 (25.8)
97 (80.8)
25.3 ± 1.3
694.5 ± 140.5
4 (0-9)
6 (0-9)
116 (96.7)
110 (91.7)
104 (86.7)
22 (18.3)
10 (8.3)
66 (55.0)
15 (12.5)
114 (95.0)
119 (99.2)
62 (51.7)
42 (35.0)
101 (84.2)
23 (19.2)
18 (15.0)
66 (55.0)
47 (39.2)
8 (6.7)
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PTX or PM, n (%)
6 (5.9)
4 (9.8)
13 (10.8)
Length of NBSCU 85.9 ± 59.0
105.3 ± 44.6
144.5 ± 92.0
Stay (d)*†
*Mean ± standard deviation
** Median (range)
† p < 0.05
DR, delivery room; BMV, bag and mask ventilation; NCPAP, nasal continuous positive
airway pressure; RDS, respiratory distress syndrome; IVH, intra-ventricular hemorrhage;
ROP, retinopathy of prematurity; NEC, necrotizing enterocolitis; PDA, patent ductus
arteriosus; PVL, periventricular leukomalacia; PTX, pneumothorax; PM,
pneumomediastinum.
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Table 2A. Unadjusted Outcomes by Extubation DOL
Extubation Group

DOL 1-3 DOL 4-7 DOL 8+
(N = 101) (N = 41)
(N = 120)
BPD, n (%)
47 (46.5)
31 (75.6)
112 (93.3)
BPD or Death, n (%)
58 (57.4)
32 (78.0)
116 (96.7)
Reintubation, n (%)
71 (70.3)
33 (80.5)
85 (70.8)
DOL: day of life; BPD: bronchopulmonary dysplasia.

P-value
< 0.0001
< 0.0001
0.43

Table 2b. Unadjusted Outcomes by Extubation DOL and Reintubation

Extubated DOL 1-3
BPD, n (%)
BPD or Death, n (%)
Extubated DOL 4-7
BPD, n (%)
BPD or Death, n (%)
Extubated DOL 8+
BPD, n (%)
BPD or Death, n (%)
DOL:
day

	
  

Reintubated
(N = 189)
N = 71
38 (53.5)
49 (69.0)
N = 33
27 (81.8)
28 (84.8)
N = 85
78 (91.8)
82 (96.5)
of
life;

Not Reintubated P-value
(N = 73)
N = 30
9 (30.0)
<0.05
9 (30.0)
0.0004
N=8
4 (50.0)
0.08
4 (50.0)
0.05
N = 35
34 (97.1)
0.43
34 (97.1)
1.0
BPD:
bronchopulmonary

dysplasia.
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Table 3. Severity of BPD by Extubation DOL*
Extubation Group

DOL 1-3 DOL 4-7 DOL 8+ P-value
(N = 38)
(N = 26)
(N = 107)
Mild BPD, n (%)
21 (55.3)
12 (46.2)
41 (38.3)
0.16
Moderate BPD, n (%)
4 (10.5)
5 (19.2)
14 (13.1)
0.60
Severe BPD, n (%)
13 (34.2)
9 (34.6)
52 (48.6)
0.19
* Infants with BPD of unknown severity (transferred prior to 36 weeks’ PMA) excluded
from table; DOL: day of life; BPD: bronchopulmonary dysplasia; PMA: post-menstrual
age.
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Table 4A. Unadjusted and Adjusted Risk of BPD by Extubation DOL
Unadjusted
Adjusted*
Extubation Group
HR (95% CI)
p-value
HR (95% CI)
DOL 4-7 vs. DOL 1-3 1.5 (0.9-2.3)
0.09
1.7 (1.0-2.8)
DOL 8+ vs. DOL 1-3 7.1 (4.9-10.1)
< 0.0001
16.9 (10.5-27.1)
DOL 8+ vs. DOL 4-7 4.5 (3.2-7.3)
< 0.0001
10.0 (6.1-16.3)

p-value
<0.05
< 0.0001
< 0.0001

Table 4B. Unadjusted and Adjusted Risk of BPD or Death by Extubation DOL
Unadjusted
Adjusted*
Extubation Group
HR (95% CI)
p-value
HR (95% CI)
p-value
DOL 4-7 vs. DOL 1-3 1.2 (0.8-1.9)
0.34
1.3 (0.8-2.2)
0.26
DOL 8+ vs. DOL 1-3 5.3 (3.8-7.5)
< 0.0001
10.7 (7.0-16.5)
< 0.0001
DOL 8+ vs. DOL 4-7 4.3 (2.9-6.5)
< 0.0001
8.1 (5.0-13.0)
< 0.0001
*Adjusted for antenatal steroid use, race, gender, multiple gestation, gestational age,
APGAR at 5 minutes, mode of delivery, delivery room resuscitation efforts, respiratory
distress syndrome, surfactant use, retinopathy of prematurity, intraventricular
hemorrhage, necrotizing enterocolitis, sepsis, patent ductus arteriosus, bowel perforation,
periventricular leukomalacia, pneumothorax, pneumomediastinum, and need for
reintubation.
BPD: bronchopulmonary dysplasia; DOL: day of life; HR: hazard ratio; CI: confidence
interval.
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Figure Legend
Figure 1. Unadjusted Kaplan-Meier Survival Plot by Extubation day of life (DOL) and
probability of no bronchopulmonary dysplasia (BPD) (1A) or no BPD or death (1B) in
the 3 categories of infants.
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Figure 1A. Unadjusted Kaplan-Meier Survival Plot by Extubation DOL (BPD)

DOL: day of life; BPD: bronchopulmonary dysplasia; PMA: postmenstrual age; * Censored subjects include infants with “no BPD” at 36
weeks’ PMA or infants who died prior to 36 weeks’ PMA.
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Figure 1B. Unadjusted Kaplan-Meier Survival Plot by Extubation DOL (BPD or
Death)

DOL: day of life; BPD: bronchopulmonary dysplasia; PMA: postmenstrual age; * Censored subjects include all surviving infants with “no
BPD” at 36 weeks’ PMA.
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Supplemental Figure Legend
Supplemental Figure 1. Flow chart showing selection of our study cohort based on
inclusion/exclusion criteria.
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Supplemental Figure 1. Flow chart of selection of our study cohort.

DOL: day of life.
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GENETIC RISK FACTORS FOR BRONCHOPULMONARY DYSPLASIA (BPD).
Jessica Berger and Vineet Bhandari, Section of Neonatology, Department of Pediatrics,
Yale University, School of Medicine, New Haven, CT.

BPD is a complex respiratory morbidity affecting premature infants. The etiology is
multifactorial, but several studies have shown BPD to have a genetic component. Few
studies have successfully identified and confirmed specific single nucleotide
polymorphisms (SNPs) associated with an increased risk of BPD. The objective of this
study is to collect samples for future sequencing for confirmation of specific SNPs as a
replication cohort. Infants born at ≤ 32 weeks’ gestational age were identified from
neonates at Yale-New Haven Children’s Hospital and collaborating institutions. Genetic
samples were collected by buccal swab from cases with BPD and controls.
Comprehensive medical histories were collected for future genotype-phenotype
correlation. 321 infants were sampled for inclusion in our study. Of these 321, 195 are
BPD cases and 126 are healthy controls. Significant differences between cohorts were
observed for race, gestational age, birth weight, APGAR scores, development of several
common neonatal comorbidities, number of days of oxygen therapy, and number of days
invasively and noninvasively ventilated. Genetic samples collected are reflective of the
demographics of the neonatal population in the ICU setting. Given the racial
heterogeneity of this population, the plan remains to use these samples for confirmation
of specific SNPs reported by other investigators.
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INTRODUCTION
Bronchopulmonary dysplasia (BPD) is a complex respiratory process that affects
premature infants. As previously described, the etiology of this disease is known to be
multifactorial, with a significant component attributed to an infant’s genetic composition.
Parker et al, in a population of 108 very low birth weight identical twins, showed
an adjusted odds ratio of 12.3 (p < 0.001) for developing BPD in a second twin if the
other twin is diagnosed, adjusting for birth order, APGAR score, and other potential
confounders

50

. Subsequently, Bhandari and Gruen examined concordance of BPD in

mono- and di-zygotic twins, showing heritability rates of up to 58.4%

51

. Lavoie et al

independently confirmed the findings of Bhandari and Gruen using similar methodology
and the updated NIH Consensus Definition of BPD. This group showed a 79-82%
heritability of BPD, specifically for moderate to severe BPD 52.
These early studies identified a genetic component to the etiology of BPD that
persisted after adjustment for key demographic and clinical factors. Subsequently,
investigators aimed to identify specific candidate genes that might contribute to the
development of BPD in the neonate. Numerous studies explored the potential role of
genes for pro-inflammatory cytokines such as interleukin (IL)-4 and tumor necrosis
factor (TNF), anti-inflammatory cytokines such as IL-10, and surfactant proteins. Many
of these studies found no associations between single nucleotide polymorphisms (SNPs)
in these specific alleles and the development of BPD in neonates 51. One study by Manar
et al. found a slightly significant association between a particular isoleucine isoform of
the gene encoding for glutathione-S-transferase-P1 (GST-P1), which degrades damaging
reactive oxygen species (ROS). This result suggested that infants afflicted with BPD
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were less efficient at removing ROS from the lung, thus increasing their risk for BPD 53.
Though the results of this and other similar studies are exciting, they are mostly limited
by small sample size and poor reproducibility in larger studies. Additionally, genetic
variations between races may lead to different results when exploring the same genes.
Wang et al, in a study of a the Chinese Han population, found statistically significant
associations between SNPs of the GST-M1 and GST-T1 alleles, both of which were not
significant in Manar et al’s study

54

. The possibility remains that racial differences, the

relative infrequency of certain SNPs in the population, or a combination of multiple SNPs
(polygenetic effect) will make it difficult to identify single genes contributing to the
development of BPD 51.
Given the mixed evidence from many small candidate gene studies pointing
towards multiple SNPs playing a role in BPD, there is value to interrogating the entire
genome in large populations. Use of genome-wide association (GWA) studies affords
investigators the ability to survey the whole genome, encompassing exons and introns,
for millions of SNPs. Since many SNPs are known to have high linkage disequilibrium,
“tag SNPs” may be used to represent clusters of SNPs to reduce the number of SNPs
scanned in a particular assay. On a population level, GWA studies use the respective
frequencies of SNPs to identify significant differences between healthy subjects and
those with disease phenotypes 55,56.
The use of GWA study methodology can be applied to many study designs,
including case-control, cohort, prospective clinical trial, and meta-analysis. GWA studies
have many advantages, including speed, affordability, and applicability to complex
diseases associated with a myriad of SNPs. There are drawbacks to this type of study,
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including stringent significance thresholds requiring large sample sizes. One way to
approach the need for a large sample size is to scan a large discovery population and then
test SNPs with significant associations in one or more replication cohorts. Though the
ideal would be to identify single gene causes for diseases of interest, the challenge of
using GWA studies in complex diseases is that they may yield dozens of hits with no
single SNP making a significant contribution in a large number of patients 55.
To date, two large GWA studies have been conducted in neonates. Hadchouel et
al used DNA pooling techniques to scan two small discovery populations, of African and
white descent, respectively. The most significant polymorphism discovered in these
populations, a variant of the SPOCK2 gene (p = 1.66 x 10-7), was replicated in a separate
population by genotyping and also in a population of Finnish ancestry. This study group
also studied mRNA levels of SPOCK2 in rat lungs in the alveolar stage of development
and found increased levels of SPOCK2 mRNA in rats exposed to hyperoxia compared to
normoxic controls. Based on their findings in GWA studies and in rat models, Hadchouel
et al suggest that SPOCK2 may play a role in alveolar development and in the impaired
alveolarization seen in BPD cases

57

. In another GWA study, Wang et al used a large

discovery population comprised of four racial groups. Using a significance threshold of 5
x 10-8, Wang et al were unable to find a significant SNP in the discovery or replication
populations. This group also investigated SNPs previously associated with BPD in other
studies, including SPOCK2, but was unable to replicate the findings of previous studies.
The variability in data may be attributed to racial differences in the study populations, as
well as differences in sample size 58.
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STATEMENT OF PURPOSE/ SPECIFIC AIMS
Based on previous work studying heritability patterns of BPD in monozygotic twins,
it is understood that there is a significant genetic component to the etiology of BPD. We
propose to utilize a large library of DNA samples from premature infants at Yale-New
Haven Children’s Hospital and other tertiary care centers to validate surveillance genes
identified by other investigators that contribute to the development of BPD. Our specific
aims are:
(1) To identify infants with BPD (“cases”) and without BPD (“controls”) hospitalized
in the NICU at Yale-New Haven Children’s Hospital and collaborating tertiary
care centers who fit inclusion criteria and to collect DNA by buccal swab.
(2) To isolate DNA from buccal swab samples using established extraction protocols.
(3) To perform high-throughput sequencing of these DNA in collaboration with the
lab of Dr. Richard Lifton in order to analyze the DNA from these infants. This
sequencing is to be used for validation of SNPs identified by other investigators.
(4) To perform genotype-phenotype analysis on these samples to identify genes
contributing to development of BPD.
Within the time frame of this study, we have completed objectives (1) and (2).
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METHODS
BPD Consortium
Prior to the initiation of this study in 2005, a BPD consortium was formed to
foster sharing of genetic samples and clinical information between participating centers.
Participating NICUs in this GWAS include Yale-New Haven Children’s Hospital (New
Haven, CT), Magee-Womens Hospital of UPMC (Pittsburgh, PA), Coastal Carolina
Neonatology (Wilmington, NC), Montefiore Medical Center (Bronx, NY), Women &
Infants Hospital (Providence, RI), Stony Brook Children’s Hospital (Stony Brook, NY),
Cincinnati Children’s Hospital (Cincinnati, OH), and University of Kentucky Children’s
Hospital (Lexington, KY). The study was approved by Yale University’s Human
Investigations Committee, as well as by an equivalent committee at all participating
institutions.
Patient Population
Our study population included infants of both genders and all races born at a
gestational age ≤ 32 weeks. We included infants with BPD (“cases”), based on the
physiologic definition at 36 weeks’ post-menstrual age (PMA) described by Jobe et al in
2001 2, and infants without BPD (“controls”). Consent was obtained and samples were
collected only after infants reached 36 weeks’ PMA.
Previous studies and review articles have discussed the myriad benefits of
studying the genetics of particular disease processes in genetically isolated populations,
including Finnish populations

59

. Given the size and racial heterogeneity of our study

population, we concluded that our study would be most powerful if a genetically isolated
population was used for discovery purposes and our population was used for replication
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of findings. To that end, we have been in communication with the laboratory of Dr.
Mikko Hallman, a neonatologist at the University of Oulu in Oulu, Finland, to use his
population of Finnish neonates for a discovery population.
DNA Collection and Extraction
DNA was collected via buccal swab using sterile, soft, cotton-tipped swabs
inserted into the oral cavity and rubbed against the buccal mucosa 10 to 20 times. One
swab was used for each cheek. Upon collection, samples were stored at -20 degrees
Centigrade until extraction. Research team members at participating institutions utilized
similar technique for sample collection; samples were overnight mailed on dry ice to
avoid degradation of genetic material.
DNA was extracted from collected buccal swabs by proteinase-k/SDS lysis with
phenol-chlorophorm extraction to degrade remaining protein material. Extracted DNA
was precipitated with 70% ethanol and rehydrated with Tris-EDTA buffer. DNA was
then stored at 4 degrees Centigrade prior to genotyping. We used spectrophotometry to
quantify DNA concentrations in each sample.
Clinical Data Collection
In order to perform subsequent genotype-phenotype correlative analysis, we
collected extensive demographic and clinical information about participating infants and
families. At the time of initial consent, demographic information was gathered, including
self-reported race. A thorough family history was obtained related to history of multiple
gestations, cardiovascular disease, respiratory illness, and developmental disorders.
Maternal medical history was also obtained, including questions concerning pre-natal
care and pregnancy, gestational diabetes, hypertension, medications, smoking, alcohol
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and drug use, miscarriages, abortions, premature births, and neonatal disease and losses if
applicable. Maternal charts were consulted when necessary to confirm the diagnosis of a
relevant disorder (i.e. chorioamnionitis), documentation by treating physicians,
pediatricians, neonatologists, or specialists, and relevant imaging limited to X-Rays and
CT scans.
Neonatal data were also collected from the electronic medical record spanning the
period from birth until discharge. Delivery room data included birth weight, gestational
age, multiple gestation, APGAR scores at 1 minute and 5 minutes, delivery room
resuscitation modalities including oxygen therapy, bag-and-mask ventilation, and
endotracheal intubation, diagnosis of respiratory distress syndrome (RDS), and surfactant
use. Data from the neonate’s clinical course, including intraventricular hemorrhage,
retinopathy of prematurity +/- need for surgery, patent ductus arteriosus +/- need for
surgical ligation, pneumothorax or pulmonary interstitial emphysema, sepsis, and
necrotizing enterocolitis, were also documented. Clinical criteria used to make these
diagnoses have been described in Chapter 1 of this thesis.
The number of days on each ventilator modality and number of days of oxygen
therapy were also recorded. At 36 weeks’ PMA, infants were designated as “cases” or
“controls” using the NIH Consensus Definition of BPD as previously described 2.
Strict confidentiality regarding this patient information was maintained
throughout the duration of the study.
Genome-Wide Association Analysis
To date, genetic and clinical data collection is ongoing and the following methods
are prospective. Collaboration with the laboratory of Dr. Richard Lifton in the
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Department of Genetics has been arranged to validate any surveillance genes identified in
a larger discovery population. Whole genome amplification (Qiagen kit) will be used for
samples that do not meet the DNA threshold for genotyping of 500 ng. For genotyping,
we will use the techniques as previously described 60. In brief, genome-wide genotyping
will be performed using the Illumina Human 610-Quad BeadChip. Samples will be
genotyped in two batches at the W.M. Keck genotyping facility of Yale University.
Approximately equal number of cases and controls will be genotyped in each batch to
protect against potential technical artifacts leading to differential bias in the analysis.
Genotypes will be called using the automated clustering algorithm in the Illumina
Genome Studio, Genotyping Module v.1.1.9. The genotyping will be performed with the
Sequenom MassARRAY (MALDI-TOF) Spectrometry system at the W.M. Keck
genotyping facility.
Statistical analysis:
Analysis of population stratification: We will control for potential population
stratification by performing stratified Cochran-Mantel-Haenszel (CMH) analysis based
on the strata defined by the cluster solution. As a confirmatory procedure, we will also
adjust for two significant eigenvectors using logistic regression. For each analysis (crude,
CMH, or PC-adjusted logistic), we will estimate a genomic inflation factor 60.
Genotype-phenotype correlations: The top SNPs representative of the independent
loci will be screened for associations with clinical phenotypes using age- and genderadjusted regression models. Linear regression will be used for quantitative phenotypes
and logistic regression for binary traits. The genotypes of specific SNPs will be used as
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predictors and coded under an additive model. All analyses will be performed using SPSS
Statistics for Windows v17.0 (SPSS, Inc., Chicago, IL).
Division of Efforts
Collection of samples and data for this project began in 2005 and has continued
through the present date. Prior to June 2012 when this student joined the team at the Yale
study site, the principal investigator, Dr. Bhandari, and other members of his research
team obtained consent, collected the samples and recorded some clinical data. Haiying
Meng, PhD, extracted DNA from Yale samples; these samples remain stored in the -80
degrees Centigrade freezer in the lab. At participating institutions, our collaborators
obtained consent, collected the samples, and recorded clinical data on institution-specific
data sheets.
Since June 2012, this student has identified appropriate subjects, obtained
informed consent, collected buccal swabs, and extracted DNA using the described
methods. This student produced all reagents for proteinase-k/SDS lysis and phenolchlorophorm extraction. This student also quantified the extracted DNA using
spectrophotometry. This student also compiled and organized extensive clinical data from
infants previously enrolled in the study and newly enrolled infants. Additionally, this
student is responsible for maintenance of Human Investigations Committee approval at
the Yale site.
Once a minimum number of samples have been collected, samples will be
transferred to our partners in the laboratory of Dr. Richard Lifton who will perform the
genotyping and statistical analysis described above in collaboration with the W.M. Keck
genotyping facility at Yale.
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RESULTS
Patient Population and Characteristics
To date, 321 infants have been enrolled from Yale and partnering institutions. An
additional 58 samples have been collected from first-degree relatives of study subjects,
including parents, grandparents, and siblings. Of the 321 study subjects, 195 (60.7%) are
“cases” and 126 (39.3%) are “controls.”
Tables 5 shows the demographics and key clinical features of the patient
population sorted by BPD diagnosis. Of note, there are many significant differences
between the BPD cohort and the control cohort. Infants with BPD were born at
significantly lower gestational ages and birth weights and were found to have
significantly lower APGAR scores at both one and five minutes in the delivery room.
Additionally, racial differences were observed between the groups. The clinical courses
of these groups of infants also varied, with infants with BPD also developing
significantly more comorbidities, including ROP, PDA, sepsis, and pneumothorax.
Infants with BPD received significantly more days of O2 therapy, as is appropriate given
the clinical definition of BPD. Those with BPD also spent more days on several
ventilator modalities, including invasive ventilation (IMV, HFOV) and nasal ventilation
(NIPPV, NCPAP).
DNA Quantification
Spectrophotometry was used to quantify the amount of DNA in the individual
samples. Of the 206 samples extracted by this student since June 2012, 185 (89.8%)
exceeded the minimum threshold of 500 ng needed for successful genotyping. These
samples included swabs collected at Yale and at other institutions. Of the 21 samples that
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did not meet the threshold, no single factor could be identified as the cause of low yield,
though variable swabbing technique and inadequate cell collection are the most likely.

	
  

51	
  

DISCUSSION
We aimed to conduct a GWA study to identify single-nucleotide polymorphisms
associated with the development of BPD, a respiratory comorbidity of prematurity with
known genetic causes. Within the constraints of time, we were able to collect nearly 400
samples from both neonates and their first-degree relatives. We were able to extract
genetic material from these samples with a high degree of success in light of the fact that
many samples had been frozen for more than one year. We also compiled a
comprehensive database of clinical information about these neonates, which will be used
in the future as part of genotype-phenotype correlation analysis. Given the rigid
significance thresholds for this type of study, which we discussed previously, our sample
size of approximately 400 is not large enough for a discovery population. To that end, we
still plan on collaborating with other investigators to identify a population that is ideal for
genetic discovery.
One of the leading investigators we have identified is Dr. Mikko Hallman of the
Oulu University Hospital in Oulu, Finland. This study group is ideal for a number of
reasons. First, Dr. Hallman has been successful in amassing a large collection of
approximately 1,000 samples. Second, Dr. Hallman’s study population is derived from a
genetically isolated population. As described by Arcos-Burgos and Muenke, the Finnish
population is ideal for genetic studies because of the founder effect, which suggests that
the population originated from a small group of individuals. It is also believed that the
Finns remained geographically isolated from other European populations for nearly two
millennia, leading to inbreeding and the presence of many recessive disorders in the
population
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identifying loci for metabolic, psychiatric, and autoimmune disorders

61-63

. Genetic

studies in Finnish neonatal populations have also been used to show allelic variation in
respiratory distress syndrome (RDS) and prematurity in general. Investigators have
shown genetic variants of surfactant proteins A and C in neonates with respiratory
distress syndrome

64,65

. Additionally, polymorphisms in the gene coding for Toll-like

receptor 4 have been associated with preterm birth in Finnish neonates 66.
One of the two previous genome-wide association studies conducted for BPD
pooled DNA in the discovery population by race to eliminate confounding by race. Using
one French population of African descent (N = 107) and one French population of white
ancestry (N = 98), Hadchouel et al. identified a polymorphism in the gene for SPOCK2
with the most significant polymorphism achieving a p-value on the order of 10-7. This
study group then used a black and white French replication population (N = 212) and a
small Finnish population (N = 213) to replicate their findings. Finally, Hadchouel et al.
identified elevated SPOCK2 mRNA levels in newborn rat lungs after exposure to
hyperoxia 57. Though this group aimed to eliminate race as a confounder by pooling DNA
into two racially distinct groups, this served to shrink an already small discovery
population. As a result, they were not able to achieve a p-value on the order of 10-8, a
threshold used by other studies 58,60. Quantification of SPOCK2 levels in newborn rats in
the alveolar stage after exposure to hyperoxia is a useful way to confirm changes in gene
expression in one animal model of BPD. However, elevation of mRNA levels does not
necessary correlate with increased protein levels. Use of tracheal aspirates to measure
protein levels in the cells would show a more convincing association between a
polymorphism in the SPOCK2 gene and changes in phenotype.
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Wang et al. also conducted a GWAS to investigate genetic variants associated
with BPD in neonates. The advantage of this study was its access to a very large
discovery population of 1,726 very low birth weight infants born in the state of
California. Their replication population comprised 795 infants of comparable
demographics and clinical characteristics. Despite access to such a large population, this
study group did not identify any significant polymorphisms associated with moderatesevere BPD as compared to mild BPD or no BPD. Wang et al. note that variability in
race, sample size, and other factors may have led to a negative result 58. Of note, several
other differences exist between Wang et al.’s study and Hadchouel et al.’s study.
Hadchouel et al.’s study was prospective, whereas Wang et al.’s study was retrospective
and used blood samples previously collected for state-mandated newborn metabolic
panels. Additionally, there was variability in the gestational ages of the populations used,
both between the two studies’ discovery populations and also between Hadchouel et al.’s
discovery and replication populations. Both of these studies used moderate-severe BPD
as their case population, which does not reflect the current NIH consensus definition
2,57,58

. Wang et al. also used a requirement of at least three days of positive pressure

ventilation (PPV) in both cases and controls so as to control for environmental exposures,
though exposure to PPV is not part of the experience for many infants without BPD 58.
Though our study has not yet been carried through to completion, one advantage
would be the availability of a large genetically isolated population for the discovery of
candidate genes to replicate in our own diverse population. With respect to our
replication population, the racial demographics are grossly different from those used by
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Wang et al, reflecting the differences in racial group predominance in our consortium
versus that of the California group 58.
Genome-wide association studies have proven valuable in the study of many
diseases with purely genetic causes or multifactorial etiologies. Though these studies
have had success in diseases such as IgA nephropathy 60, success has been mixed in BPD,
suggesting a complex interplay of genetic and environmental risk factors. Nevertheless,
convincing evidence pointing towards the genetic contribution to BPD indicates that this
is a disease area ripe for ongoing study using the most advanced technology for genetic
mapping. We aim to continue this project with the objective of identifying and validating
important genes in the development of such a complex and morbid disease.
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Table 5. Demographics of Genome-Wide Association Study Population
BPD Cases (N = 195)
170 (87.2)

Controls (N = 126)
111 (88.1)

p-value
0.86
0.0016

Antenatal steroids, n (%)
Race, n (%) †
White
116 (59.5)
54 (42.9)
Black
59 (30.3)
41 (32.5)
Asian
1 (0.5)
3 (2.4)
Hispanic
17 (8.7)
19 (15.1)
Native American, Biracial or 2 (1.0)
9 (7.1)
Other
Male gender, n (%)
102 (52.3)
68 (54.0)
0.82
Multiple gestation, n (%)
74 (37.9)
55 (43.7)
0.35
Caesarean delivery, n (%)
143 (73.3)
87 (69.0)
0.45
Gestational age (wks)* †
26.2 ± 1.9
29.5 ± 1.7
< 0.0001
Birth weight (g)* †
822.4 ± 243.4
1315 ± 333.9
< 0.0001
APGAR 1 minute** †
4 (0-9)
7 (0-9)
< 0.0001
APGAR 5 minutes** †
7 (1-9)
8 (0-9)
< 0.0001
RDS, n (%) †
182 (93.3)
76 (60.3)
< 0.0001
Anytime surfactant, n (%) †
184 (94.4)
66 (52.4)
< 0.0001
Postnatal steroids, n (%) †
25 (12.8)
0 (0.0)
< 0.0001
IVH, n (%)
74 (37.9)
42 (33.3)
0.41
ROP, n (%) †
134 (68.7)
15 (11.9)
< 0.0001
NEC, n (%)
18 (9.2)
10 (7.9)
0.84
PDA, n (%) †
120 (61.5)
20 (15.9)
< 0.0001
Sepsis, n (%) †
90 (46.2)
16 (12.7)
< 0.0001
PVL, n (%)
13 (6.7)
3 (2.4)
0.12
PTX, n (%) †
22 (11.3)
6 (4.8)
< 0.05
Duration
of
invasive 28.4 ± 35.2
2.2 ± 5.4
< 0.0001
ventilation (d)* †
Duration of NIPPV (d)* †
3.3 ± 7.5
1.3 ± 3.4
0.01
Duration of NCPAP (d)* †
20.9 ± 22.9
4.8 ± 7.0
< 0.0001
Days supplemental O2 (d)* † 79.2 ± 47.6
7.3 ± 7.6
< 0.0001
*Mean ± standard deviation
** Median (range)
† p < 0.05
RDS, respiratory distress syndrome; IVH, intra-ventricular hemorrhage; ROP,
retinopathy of prematurity; NEC, necrotizing enterocolitis; PDA, patent ductus
arteriosus; PVL, periventricular leukomalacia; PTX, pneumothorax; Invasive ventilation
includes synchronized intermittent mandatory ventilation (SIMV) and high frequency
oscillatory ventilation (HFOV); NIPPV, nasal intermittent positive pressure ventilation;
NCPAP, nasal continuous positive airway pressure; O2, oxygen.
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